FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:504-506 February 17, 1994 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Fuster, V. Related Article by The GUSTO Investigators PubMed Citation

To the Editor: After an intensive marketing campaign by Genentech, the report by the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) investigators (Sept. 2 issue)¹ has finally appeared. In view of the small survival advantage conferred by tissue plasminogen activator (t-PA) (0.9 percent -- an effect evident only when it is administered within four hours after the onset of symptoms), the increased risk of stroke, and the striking difference in the expense of therapy (a difference of $220,000 to save a single life: $2,300 - $320 x 100 divided by 0.9), the fact that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Cunningham, D (1995). Controversies in Management: Important progress in treatment. BMJ 310: 247-248 [Full Text]